Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name DCC-3116
Trade Name
Synonyms DCC 3116|DCC3116
Drug Descriptions

DCC3116 selectively inhibits ULK1/2, leading to decreased phosphorylation of its substrate ATG13 and inhibition of autophagosome formation, and may lead to inhibition of tumor cell growth (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B129).

DrugClasses
CAS Registry Number NA
NCIT ID C180331

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Afatinib + DCC-3116 Afatinib DCC-3116 0 0
Binimetinib + DCC-3116 Binimetinib DCC-3116 0 1
Cetuximab + DCC-3116 + Encorafenib Cetuximab DCC-3116 Encorafenib 0 1
DCC-3116 DCC-3116 0 1
DCC-3116 + Osimertinib DCC-3116 Osimertinib 0 0
DCC-3116 + Ripretinib DCC-3116 Ripretinib 0 1
DCC-3116 + Sotorasib DCC-3116 Sotorasib 0 1
DCC-3116 + Trametinib DCC-3116 Trametinib 0 1


Additional content available in CKB BOOST